Arbutus Biopharma Corporation

XNASHealth care

Last traded price · USD

$4.03

−0.74%Delayed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 20:06 IST · A quote does not mean the product is available to trade on your account.

Day's open: $4.02
Previous close: $4.06
Volume: 106,222
Day's high: $4.06
Day's low: $4.00

In brief

Arbutus Biopharma Corporation is a health care company listed on Nasdaq, valued at about $798M.
Its shares closed at $4.06 on 4 Nov 2026, down 9.8% over the past year.
From India you can buy ABUS in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Arbutus Biopharma Corporation (ABUS) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole ABUS share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade ABUS options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Behind SPY and its sector fund XLV over 1 year
1 month: −9.4% (SPY −1.6%, XLV +13.5%). 3 months: −12.1% (SPY −0.4%, XLV +15.5%). 1 year: −9.8% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: ABUS, SPY and XLV · as of 4 Nov 2026
Short interest at 12.4% of shares outstanding
24.6M shares were sold short at the 15 Oct 2026 settlement, 12.4% of the 198.1M shares outstanding; covering them would take 4.3 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Below its 50- and 200-day averages
The 4 Nov 2026 close of $4.06 was 12.5% below its 50-day average ($4.64) and 9.6% below its 200-day average ($4.49). It has closed below the 200-day for 22 sessions, since 6 Oct 2026. The 50-day average crossed above the 200-day on 8 Jul 2026, 84 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
Light volume: 0.5× its 30-session average on 4 Nov 2026
4 Nov 2026 volume of 2.8M shares was 0.5× the average of the 30 sessions before it (5.7M), as the price rose 4.6%. SPY traded 1.5× its own average that session.
Daily volume against a 30-session baseline · as of 4 Nov 2026
29% of the way up its 52-week range
Closed at $4.06 on 4 Nov 2026: 25.5% below the 52-week high of $5.45 (21 Aug 2026) and 16.0% above the low of $3.50 (2 Feb 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−9.4%

6 months−8.1%

1 year−9.8%

5 years+4.6%

Newswire

About

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Website

Notable moves

January 16, 2026
−13.62%
April 3, 2024
+15.87%
December 1, 2021
+44.06%

Newswire

About

Website

Notable moves

January 16, 2026
−13.62%
April 3, 2024
+15.87%
December 1, 2021
+44.06%

Arbutus Biopharma Corporation

XNASHealth care

Last traded price · USD

$4.03

−0.74%Delayed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 20:06 IST · A quote does not mean the product is available to trade on your account.

Day's open: $4.02
Previous close: $4.06
Volume: 106,222
Day's high: $4.06
Day's low: $4.00

In brief

Arbutus Biopharma Corporation is a health care company listed on Nasdaq, valued at about $798M.
Its shares closed at $4.06 on 4 Nov 2026, down 9.8% over the past year.
From India you can buy ABUS in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Arbutus Biopharma Corporation (ABUS) shares from India?

Do I need the price of a whole ABUS share to invest?

How much can I invest in US stocks in a year?

Can I trade ABUS options or futures?

Insights

Quotes run fifteen minutes behind.

Behind SPY and its sector fund XLV over 1 year
1 month: −9.4% (SPY −1.6%, XLV +13.5%). 3 months: −12.1% (SPY −0.4%, XLV +15.5%). 1 year: −9.8% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: ABUS, SPY and XLV · as of 4 Nov 2026
Short interest at 12.4% of shares outstanding
24.6M shares were sold short at the 15 Oct 2026 settlement, 12.4% of the 198.1M shares outstanding; covering them would take 4.3 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Below its 50- and 200-day averages
The 4 Nov 2026 close of $4.06 was 12.5% below its 50-day average ($4.64) and 9.6% below its 200-day average ($4.49). It has closed below the 200-day for 22 sessions, since 6 Oct 2026. The 50-day average crossed above the 200-day on 8 Jul 2026, 84 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
Light volume: 0.5× its 30-session average on 4 Nov 2026
4 Nov 2026 volume of 2.8M shares was 0.5× the average of the 30 sessions before it (5.7M), as the price rose 4.6%. SPY traded 1.5× its own average that session.
Daily volume against a 30-session baseline · as of 4 Nov 2026
29% of the way up its 52-week range
Closed at $4.06 on 4 Nov 2026: 25.5% below the 52-week high of $5.45 (21 Aug 2026) and 16.0% above the low of $3.50 (2 Feb 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−9.4%

6 months−8.1%

1 year−9.8%

5 years+4.6%

Newswire

About

Website

Notable moves

January 16, 2026
−13.62%
April 3, 2024
+15.87%
December 1, 2021
+44.06%

Newswire

About

Website

Notable moves

January 16, 2026
−13.62%
April 3, 2024
+15.87%
December 1, 2021
+44.06%

Arbutus Biopharma Corporation

Arbutus Biopharma Corporation in brief

Behind SPY and its sector fund XLV over 1 year

Short interest at 12.4% of shares outstanding

Below its 50- and 200-day averages

Light volume: 0.5× its 30-session average on 4 Nov 2026

29% of the way up its 52-week range

Arbutus Biopharma Corporation

Arbutus Biopharma Corporation in brief

Behind SPY and its sector fund XLV over 1 year

Short interest at 12.4% of shares outstanding

Below its 50- and 200-day averages

Light volume: 0.5× its 30-session average on 4 Nov 2026

29% of the way up its 52-week range